First Time Loading...
A

Arecor Therapeutics PLC
LSE:AREC

Watchlist Manager
Arecor Therapeutics PLC
LSE:AREC
Watchlist
Price: 137.5 GBX Market Closed
Updated: May 5, 2024
Section:
 

Wall Street
Price Targets

AREC Price Targets Summary
Arecor Therapeutics PLC

Wall Street analysts forecast AREC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AREC is 480.42 GBX with a low forecast of 407.03 GBX and a high forecast of 565.95 GBX.

AREC Lowest Forecast
Wall Street Target
407.03 GBX
196% Upside
AREC Average Forecast
Wall Street Target
480.42 GBX
249% Upside
AREC Highest Forecast
Wall Street Target
565.95 GBX
312% Upside
Lowest
Price Target
407.03 GBX
196% Upside
Average
Price Target
480.42 GBX
249% Upside
Highest
Price Target
565.95 GBX
312% Upside
Arecor Therapeutics PLC Competitors:
Price Targets
COX
Nicox SA
401% Upside
9995
RemeGen Co Ltd
46% Upside
KRTX
Karuna Therapeutics Inc
2% Downside
MRKR
Marker Therapeutics Inc
202% Upside
COX
Nicox SA
401% Upside
9995
RemeGen Co Ltd
46% Upside
KRTX
Karuna Therapeutics Inc
2% Downside
MRKR
Marker Therapeutics Inc
202% Upside
ZEAL
Zealand Pharma A/S
30% Upside
ZYME
Zymeworks Inc
76% Upside
E
206650
EuBiologics Co Ltd
5% Upside
TWST
Twist Bioscience Corp
2% Upside

Revenue
Forecast

Revenue Estimate
Arecor Therapeutics PLC

For the last 5 years the compound annual growth rate for Arecor Therapeutics PLC's revenue is 12%. The projected CAGR for the next 3 years is 74%.

12%
Past Growth
74%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Arecor Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Arecor Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
AREC intrinsic value, competitors valuation, and company profile.
DCF Valuation
AREC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AREC stock valuation using valuation multiples.
Wall Street Estimates
AREC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AREC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AREC's stock price target?
Price Target
480.42 GBX

According to Wall Street analysts, the average 1-year price target for AREC is 480.42 GBX with a low forecast of 407.03 GBX and a high forecast of 565.95 GBX.

What is Arecor Therapeutics PLC's Revenue forecast?
Projected CAGR
74%

For the last 5 years the compound annual growth rate for Arecor Therapeutics PLC's revenue is 12%. The projected CAGR for the next 3 years is 74%.

ALPHA SPREAD
Join more than 134,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.